Biotechnology: delivering on the promise.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 20371460.
- Also identified by DOI 10.1126/scitranslmed.3000357.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The research and development of innovative new therapies are expensive and risky processes, and companies require substantial resources if they are to translate basic science into modern biomedical products. When resources are limited, as in the current economic climate, biotechnology start-up companies are often among the first casualties in the fight for assets. Policy-makers can play an important role in bolstering these important innovators.
Medical subject headings
- Biotechnology